These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35757304)

  • 1. Immune checkpoints in thymic epithelial tumors: challenges and opportunities.
    Girard N
    Immunooncol Technol; 2019 Oct; 3():8-14. PubMed ID: 35757304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmunity in thymic epithelial tumors: a not yet clarified pathologic paradigm associated with several unmet clinical needs.
    Perrino M; Voulaz E; Balin S; Cazzato G; Fontana E; Franzese S; Defendi M; De Vincenzo F; Cordua N; Tamma R; Borea F; Aliprandi M; Airoldi M; Cecchi LG; Fazio R; Alloisio M; Marulli G; Santoro A; Di Tommaso L; Ingravallo G; Russo L; Da Rin G; Villa A; Della Bella S; Zucali PA; Mavilio D
    Front Immunol; 2024; 15():1288045. PubMed ID: 38629065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paraneoplastic and Therapy-Related Immune Complications in Thymic Malignancies.
    Lippner EA; Lewis DB; Robinson WH; Katsumoto TR
    Curr Treat Options Oncol; 2019 Jun; 20(7):62. PubMed ID: 31227926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular and Functional Key Features and Oncogenic Drivers in Thymic Carcinomas.
    Barachini S; Pardini E; Burzi IS; Sardo Infirri G; Montali M; Petrini I
    Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor.
    Jing X; Zhu H; Li Y; Jia W; Zhai X; Li J; Yu J
    Immunotherapy; 2022 Oct; 14(14):1097-1107. PubMed ID: 36093721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corpuscular thymoma: entity or variant of organotypical thymomas WHO B2/B3?
    Laeng RH; Eimoto T; Kuo TT; Zettl A; Marx A; Moschopulos M; Tateyama H; Shimokawa K
    Pathol Res Pract; 2006; 202(10):697-704. PubMed ID: 16887284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levels of Tc17 cells in thymic epithelial cell tumors associated with autoimmune diseases.
    Li J; Chen Y; Wang Y; Liu Y; Zhang P
    Mediastinum; 2019; 3():8. PubMed ID: 35118237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MIC2 antibody 013. Practical application for the study of thymic epithelial tumors.
    Chan JK; Tsang WY; Seneviratne S; Pau MY
    Am J Surg Pathol; 1995 Oct; 19(10):1115-23. PubMed ID: 7573670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors.
    Tateo V; Manuzzi L; De Giglio A; Parisi C; Lamberti G; Campana D; Pantaleo MA
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33260538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.
    Moser B; Janik S; Schiefer AI; Müllauer L; Bekos C; Scharrer A; Mildner M; Rényi-Vámos F; Klepetko W; Ankersmit HJ
    PLoS One; 2014; 9(4):e94118. PubMed ID: 24705787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and pathological aspects of thymic epithelial tumors.
    Okumura M; Shiono H; Minami M; Inoue M; Utsumi T; Kadota Y; Sawa Y
    Gen Thorac Cardiovasc Surg; 2008 Jan; 56(1):10-6. PubMed ID: 18213465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Management of Thymic Epithelial Tumors: A Double-Edged Sword.
    Ballman M; Zhao C; McAdams MJ; Rajan A
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demonstration of phenotypic abnormalities of thymic epithelium in thymoma including two cases with abundant Langerhans cells.
    Kraus VB; Harden EA; Wittels B; Moore JO; Haynes BF
    Am J Pathol; 1988 Sep; 132(3):552-62. PubMed ID: 3261946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma.
    Katsuya Y; Fujita Y; Horinouchi H; Ohe Y; Watanabe S; Tsuta K
    Lung Cancer; 2015 May; 88(2):154-9. PubMed ID: 25799277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in thymic epithelial tumors: tissue predictive biomarkers for immune checkpoint inhibitors.
    Lucà S; Accardo M; Campione S; Franco R
    Explor Target Antitumor Ther; 2024; 5(3):465-476. PubMed ID: 38966177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Narrative review of immunotherapy in thymic malignancies.
    Benitez JC; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3001-3013. PubMed ID: 34295693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathomechanisms of paraneoplastic myasthenia gravis.
    Ströbel P; Preisshofen T; Helmreich M; Müller-Hermelink HK; Marx A
    Clin Dev Immunol; 2003 Mar; 10(1):7-12. PubMed ID: 14575152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological aspects of malignant and benign thymic disorders.
    Müller-Hermelink HK; Marx A
    Ann Med; 1999 Oct; 31 Suppl 2():5-14. PubMed ID: 10574149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of the immune system in thymic malignancies.
    Weksler B; Lu B
    J Thorac Oncol; 2014 Sep; 9(9 Suppl 2):S137-42. PubMed ID: 25396311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
    Perrino M; Cordua N; De Vincenzo F; Borea F; Aliprandi M; Cecchi LG; Fazio R; Airoldi M; Santoro A; Zucali PA
    Cancers (Basel); 2023 Nov; 15(23):. PubMed ID: 38067278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.